LATAM MedTech Insights

This week, we dissect a major regulatory shift in Brazil's MedTech landscape. ANVISA has just rolled out its new strategic framework for Software as a Medical Device (SaMD) and AI, aiming to align with global standards. But what does this mean for the innovators on the ground?. While harmonization promises safer and more effective digital health tools, the new requirements could inadvertently create significant barriers for local startups. This episode explores how the heightened demands for clinical data and cybersecurity might give large multinational corporations a distinct advantage in one of Latin America's biggest markets. **Case In Point:** Consider a promising Brazilian startup that has developed an AI-powered tool for early cancer detection. They were on the verge of launching, but ANVISA's new rules now demand a level of clinical evidence and cybersecurity documentation that triples their projected costs and delays their market entry by a year. They're now facing a critical pain point: can they secure new funding to meet these demanding standards before a well-funded international competitor with existing global approvals captures the market?. **Key Takeaways:** - How do ANVISA's new SaMD rules fundamentally differ from the previous regulations?. - What specific cybersecurity vulnerabilities must Brazilian MedTech startups now address to be compliant?. - Can leveraging an existing FDA clearance or CE marking truly fast-track the new ANVISA process?. - What are the three biggest mistakes a local company can make when submitting their new SaMD technical dossier?. - Is the cost of compliance under the new framework becoming prohibitive for early-stage innovators?. - How does this regulatory shift impact investment trends in Brazil's burgeoning digital health sector?. - What are the specific changes to the list of Equivalent Foreign Regulatory Authorities and how can you leverage them?. Navigating these turbulent regulatory waters is where Pure Global excels. We offer end-to-end regulatory consulting for MedTech and IVD companies, leveraging local expertise in Brazil and over 30 other markets. From initial regulatory strategy and AI-powered technical dossier preparation to acting as your local in-country representative, we streamline your path to market. Don't let regulatory hurdles block your innovation. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn how our technology and expert team can accelerate your global market access.

In this episode of LATAM MedTech Insights, we dissect the breaking news from Brazil. In the final week of March 2026, ANVISA released a surprise guidance document for Software as a Medical Device (SaMD), creating immediate and significant new hurdles for foreign manufacturers. We explore the specific changes to clinical data requirements and cybersecurity protocols that have caught the industry off guard. This isn't just a minor update; it's a fundamental shift in how digital health products will be evaluated and approved in Latin America's largest market. We explain why your existing global data might suddenly be invalid and what this means for your product launch timelines and budgets, offering a clear-eyed look at the new landscape. **A Case in Point:** Imagine a promising European MedTech company, weeks from launching its revolutionary AI diagnostic tool in Brazil. Their strategy was solid, based on their successful EU MDR approval. But overnight, ANVISA's new guidance invalidates their clinical data and demands a local cybersecurity infrastructure they don't have. Their launch is frozen, and millions in projected revenue are at risk. This is the exact challenge many companies are now facing. **Key Questions Answered in This Episode:** * What are the most critical changes in ANVISA's new SaMD guidance you must know? * How does the new emphasis on local Brazilian patient data impact your clinical strategy? * Is your current cybersecurity framework compliant with the new mandatory protocols? * Why is a CE mark or FDA clearance no longer a shortcut for entering the Brazilian market? * What are the three most common mistakes foreign companies are making in response to this news? * How can this regulatory hurdle be turned into a competitive advantage? To navigate the complexities of global market access, you need a partner with deep local expertise and a global perspective. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, using advanced AI and data tools to streamline market entry. Don't let regulatory surprises derail your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn how we can secure your market access in Brazil and beyond.

This episode of LATAM MedTech Insights dives into the immediate fallout from ANVISA's sudden enforcement of its Unique Device Identification (UDI) system in Brazil. We unpack the operational chaos this is causing for MedTech manufacturers who were unprepared for the complex data submission and labeling requirements. We explore how this regulatory shift is more than a bureaucratic hurdle. it represents a fundamental change in what it takes to access and succeed in Latin America's largest market. We discuss the critical role of the Brazil Registration Holder (BRH) and how a simple data mismatch can derail an entire product launch. A specific case we're seeing is a European scale-up whose fully approved diagnostic device is now blocked from the Brazilian market. Their multi-million dollar launch is on hold, not due to product quality, but because of a failure to meet the new UDI data submission protocols before their shipment arrived, a critical detail that has jeopardized their entire market entry strategy. Key Takeaways This Episode: 1. Why is ANVISA's new UDI enforcement causing a crisis for even experienced MedTech companies? 2. What are the most common mistakes manufacturers make when submitting UDI data to the Brazilian database? 3. How can your choice of a Brazil Registration Holder make or break your market access right now? 4. Is this UDI requirement just a Brazilian issue, or is it the blueprint for the rest of Latin America? 5. What are the hidden costs of UDI non-compliance that go far beyond regulatory fines? 6. How does this new rule impact your existing supply chain and logistics in Brazil? 7. Are your global technical dossiers truly prepared for these new local data integration demands? Navigating complex regulatory landscapes is our expertise. Pure Global offers end-to-end solutions for MedTech companies, combining local, in-country experts with advanced AI tools to streamline global market access. From regulatory strategy and technical dossier submission to serving as your local representative in Brazil, we ensure you are always ahead of the curve. Don't let regulatory surprises disrupt your growth. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

In this episode of LATAM MedTech Insights, we dissect the sudden and impactful new regulation from Brazil's ANVISA that is reshaping the landscape for Software as a Medical Device (SaMD). International manufacturers are now facing unprecedented requirements for localized clinical data and stringent cybersecurity protocols, effectively rewriting the rulebook for market access in Latin America's largest economy. We explore the immediate consequences of this regulatory shift, moving beyond the headlines to analyze the strategic and financial implications. We discuss why existing clinical data from bodies like the FDA or the EU may no longer be sufficient for ANVISA and what this means for your product launch timeline. This episode provides the critical insights you need to understand and navigate this challenging new environment. **Key Takeaways This Episode:** * How does Brazil's new rule redefine the clinical data requirements for AI-driven SaMD? * What are the specific cybersecurity mandates that international manufacturers are most likely to overlook? * Why might your existing technical dossier be immediately rejected under this new framework? * What is the single biggest mistake companies make when adapting their global strategy for Brazil's new regulations? * Are there new local data residency requirements you haven't considered for your cloud-based platform? * How can you turn this new regulatory hurdle into a competitive advantage? Navigating sudden regulatory shifts is a core challenge for global MedTech companies. At Pure Global, we offer end-to-end regulatory consulting solutions, combining deep local expertise in markets like Brazil with advanced AI and data tools to streamline your market access. From developing a new clinical strategy to ensuring your cybersecurity plan meets ANVISA's strict standards, we act as your local partner to turn regulatory complexity into a clear pathway to success. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn how we can help.

In this episode of LATAM MedTech Insights, we dissect the groundbreaking new regulation from Brazil's ANVISA, RDC 922/2026, which just rewrote the rules for AI-powered medical software. This isn't just an update; it's a seismic shift that introduces mandatory local clinical data requirements, impacting market access timelines and costs for foreign manufacturers. We explore the immediate consequences for MedTech innovators, especially those relying on existing FDA or CE Mark approvals. Learn what this increased scrutiny means for your product's classification, the validation process, and your overall launch strategy in Latin America's largest market. **Case In Point:** A promising US-based AI diagnostics company had their Brazilian launch plans shattered overnight by the new RDC 922. Their reliance on FDA clinical data is no longer enough, forcing them into an unexpected, costly, and lengthy local clinical study. Their entire LATAM expansion is now in jeopardy, a stark reminder that global regulatory approvals don't guarantee local market access. **This Episode's Key Questions:** - How does ANVISA's new RDC 922/2026 specifically reclassify AI diagnostic software? - Are my existing FDA or CE Mark clinical studies now invalid for a Brazilian submission? - What are the new mandatory requirements for local clinical data from the Brazilian population? - How will this regulatory shift impact the cost and timeline for market entry into Brazil? - What are the critical mistakes to avoid when adapting your technical dossier for this new framework? - Could this new Brazilian regulation signal a coming trend for other LATAM markets like Mexico or Colombia? - How can you turn this regulatory hurdle into a competitive advantage? Navigating complex, sudden regulatory changes is our specialty. Pure Global offers end-to-end regulatory consulting, combining local expertise with advanced AI tools to streamline global market access for MedTech and IVD companies. Don't let regulatory surprises derail your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to secure your path to market.

In this episode, we dissect a sudden and critical regulatory update from Brazil's ANVISA that was issued just last week. The new instruction imposes stringent cybersecurity and data handling requirements on all Software as a Medical Device (SaMD) and connected devices, catching many international manufacturers off guard and putting existing market approvals at risk. We explore the specific technical and documentation changes now required, from mandatory penetration testing to new data localization rules. This shift forces companies to rethink their entire compliance and operational strategy for Latin America's largest market. A case in point: A successful foreign manufacturer of remote patient monitoring tools, already established in Brazil, now faces an urgent compliance crisis. Their current registration is invalid, and they must rapidly re-engineer their product's data architecture and conduct a full cybersecurity audit to avoid being forced off the market. This is a costly and complex challenge that could halt their regional revenue stream. Key Takeaways: * What are the specific cybersecurity demands in ANVISA's new instruction for connected devices? * Do your existing products in Brazil now face an immediate compliance gap? * How will the new data localization rules impact your operational costs and IT infrastructure? * What is the new role and liability of local importers in ensuring device cybersecurity? * Are you prepared for a complete technical dossier re-submission for your software-based devices? * Why is Brazil making this sudden move, and which countries in LATAM are likely to follow? * How can this regulatory hurdle be turned into a competitive advantage? Struggling to keep up with unpredictable regulatory changes in LATAM? Pure Global offers end-to-end regulatory consulting, leveraging local expertise and advanced AI to streamline market access. Whether it's navigating Brazil's new cybersecurity rules or expanding into Mexico and Colombia, we act as your local representative to secure and maintain your market presence. Contact us for a strategic consultation at info@pureglobal.com or visit https://pureglobal.com/.

Brazil's medical device authority has just unveiled a new framework for AI technologies, signaling a gold rush for innovators in the region. This new resolution promises a clearer path to market for cutting-edge software as a medical device, opening doors to Latin America's largest healthcare economy. But hidden within this opportunity is a critical challenge that could stop foreign companies in their tracks. The regulation mandates strict adherence to Brazil's General Data Protection Law (LGPD), a complex and demanding data privacy standard. This episode of LATAM MedTech Insights unpacks the new AI resolution, exposing the hidden compliance traps and what it really takes to succeed in this promising market. **A Case Study in Foresight:** An American AI diagnostic firm sees the news from Brazil and fast-tracks its expansion plan. Their device, already FDA-cleared, seems like a perfect fit. But their submission is quickly flagged. The reason? Their cloud data processing is handled on servers in the United States, a direct violation of the unwritten expectation of LGPD compliance for local data handling. Their market entry is now frozen, facing the unexpected and costly decision of whether to build new data infrastructure just for one market. **Key Takeaways:** * What is CFM Resolution 2,454/2026 and why is it more than just an approval pathway? * How does Brazil's LGPD law create a unique regulatory hurdle for AI medical devices? * Why might your global data strategy be incompatible with the Brazilian market? * What are the potential costs associated with data localization for MedTech companies? * How can a "privacy-by-design" approach give you a competitive advantage in Brazil? * What are the key differences between LGPD and GDPR that you must know? * Why is understanding the local regulatory culture just as important as reading the rules? At Pure Global, we specialize in navigating these complex regulatory landscapes. We offer end-to-end solutions, from developing your regulatory strategy to acting as your local representative in Brazil and over 30 other markets. Our combination of local expertise and advanced AI tools streamlines your path to market access. Don't let regulatory hurdles block your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

In this episode, we dive into the landmark new resolution from Brazil’s Federal Council of Medicine (CFM) that creates a specific regulatory framework for Artificial Intelligence in medicine. This is a pivotal moment for digital health in Latin America, establishing new rules for physician oversight, data privacy, and the responsibilities of technology providers. We explore the immediate impact on MedTech and IVD manufacturers aiming to launch AI-powered solutions in the Brazilian market. This isn't just a guideline for doctors. it's a new set of requirements for the tools they use. We break down what this means for product design, technical documentation, and your overall market access strategy in Brazil. **Case Study:** A European MedTech firm has a powerful AI diagnostic software for radiology. They considered Brazil a prime market but were operating in a grey area. Now, the CFM resolution provides a path, but one with new obstacles. How must they adapt their AI's user interface to meet the "human oversight" mandate, and how can they prove their data processing is fully compliant with Brazil's stringent LGPD privacy law without a costly redesign? **Key Takeaways:** - How does the CFM's focus on physician liability change your product's risk management file? - Is your AI's algorithm explainable enough to meet the new transparency requirements? - What specific steps must you take to ensure your data practices are compliant with both the CFM resolution and Brazil's LGPD? - How will you need to modify your training and support materials for Brazilian medical professionals? - Does this new resolution require a separate clinical validation study for the Brazilian population? - How could this physician-centric framework in Brazil influence future AI regulations in other LATAM countries? At Pure Global, we offer end-to-end regulatory consulting solutions for Medical Technology and In-Vitro Diagnostic companies. We combine local expertise with advanced AI and data tools to streamline your global market access, including navigating complex new frameworks like Brazil's AI regulations. To get your product to market efficiently and correctly, contact us at info@pureglobal.com or visit https://pureglobal.com/.

This week on LATAM MedTech Insights, we dive into the seismic shift in Brazil's digital health market. ANVISA just launched its 'Agiliza-IA' program, promising to approve AI-powered diagnostic software in a record 90 days. This could unlock one of the largest markets in Latin America for SaMD innovators. But there's a catch. While the speed is tempting, the program introduces formidable new barriers. Consider a European company with a market-leading AI tool. They're ready to enter Brazil, but now face an unexpected demand for clinical trials conducted exclusively on Brazilian patients. This single requirement could delay their entry by a year and cost millions. Is the fast-track worth the price? Key Takeaways: - What exactly is ANVISA's new "Agiliza-IA" program? - Why are the new local clinical data requirements a game-changer for foreign companies? - What are the specific cybersecurity protocols you must now meet for approval? - How did a local startup beat global giants to the first approval? - Is Brazil's 90-day promise a real opportunity or a hidden trap? - What does this mean for the future of MedTech regulation across LATAM? - How can you start preparing your technical dossier for this new pathway today? At Pure Global, we specialize in turning these regulatory puzzles into market access victories. We offer end-to-end consulting for MedTech and IVD companies, leveraging local expertise and advanced AI tools to streamline your entry into over 30 global markets, including Brazil. Don't let complex regulations be a barrier to your growth. Contact Pure Global at info@pureglobal.com or visit us at https://pureglobal.com/ to learn how we can accelerate your journey.

This week, we dive into a landmark regulatory shift in Brazil. ANVISA has just unveiled a new "Reliance" pathway, promising an incredible 80% reduction in review time for medical devices already approved by MDSAP authorities. This could dramatically accelerate market access for many international firms. However, this new shortcut comes with a critical catch. At the same time, ANVISA has implemented stricter, IMDRF-aligned standards for essential safety and performance requirements. This means the technical documentation bar has been raised significantly, potentially creating new hurdles even for experienced manufacturers. We break down the opportunity and the hidden challenge. We explore the case of a U.S. orthopedic implant company, whose dream of a fast-track approval was met with the harsh reality of a complete technical file overhaul, forcing them to navigate the gap between their existing FDA compliance and Brazil's new, tougher standards. This week, you'll learn: - What are the exact eligibility criteria for ANVISA's new Reliance pathway? - How does the new RDC 848 resolution change your technical documentation checklist forever? - Which common gaps exist between an FDA-approved file and the new IMDRF-based requirements? - Is the Reliance pathway a guaranteed approval, or are there still hidden pitfalls? - What is the first step your company should take right now to adapt to this new landscape? - How can you leverage your existing international approvals most effectively for the Brazilian market? - What are the critical risk management updates required under the new regulations? Navigating the complexities of global markets is our expertise. At Pure Global, we provide end-to-end regulatory consulting for MedTech and IVD companies, using local expertise and advanced data tools to streamline your market access. Whether it's adapting your technical dossier for Brazil's new standards or acting as your local representative, we clear the path for your innovation. Contact us at info@pureglobal.com or visit https://pureglobal.com/.

Brazil's MedTech landscape is shifting. A quiet but powerful new technical note from ANVISA has just redefined the rules for AI-powered medical devices, creating immediate hurdles for global manufacturers. This update directly links cybersecurity and data privacy to the core of the device approval process, impacting all new and pending registrations. In this episode, we dissect the three critical areas of this clarification, from new clinical data expectations to the now-mandatory Software Bill of Materials (SBOM). We explore how ANVISA is tightening its alignment with Brazil's General Data Protection Law (LGPD) and what it means for your technical dossier. This is essential listening for any innovator looking to enter or expand within Latin America's largest market. Case Study Spotlight: Imagine your cutting-edge AI diagnostic software is deep into the ANVISA review process, and your launch in Brazil seems imminent. Suddenly, your application is stalled by a list of unexpected technical questions about cybersecurity monitoring and LGPD compliance, topics your initial submission only briefly touched upon. Your team must now scramble to produce new documentation that meets these unwritten rules, delaying your market entry by months and putting you behind competitors. What’s your next move. Key Takeaways: - What are the three most critical changes in ANVISA's new interpretation of AI SaMD regulations. - How does this technical note immediately affect your pending medical device submission in Brazil. - Why has a Software Bill of Materials (SBOM) suddenly become essential for approval. - Is your current cybersecurity plan robust enough to satisfy both ANVISA and Brazil's LGPD. - What specific documentation do you need to prepare now to avoid registration delays. - How can you transform this new regulatory challenge into a powerful competitive advantage. At Pure Global, we specialize in navigating these complex and evolving regulatory landscapes. Our team of local experts in Brazil, combined with advanced AI and data tools, provides end-to-end solutions to ensure your MedTech and IVD products achieve and maintain market access. From initial regulatory strategy and dossier submission to post-market surveillance, we streamline your path into over 30 global markets. Don't let unexpected regulatory shifts derail your expansion. Contact Pure Global at info@pureglobal.com or visit https://pureglobal.com/ to secure your market presence.

Last week, Mexico's regulatory body, COFEPRIS, enhanced its partnership with the U.S. FDA, launching a new phase of its fast-track program for medical devices. This creates an accelerated approval pathway for devices already cleared in the United States, representing a landmark shift in the region's regulatory landscape. This episode dissects the massive opportunity this presents, which can cut market entry timelines from years down to just months. We explore which devices qualify, the detailed submission requirements, and what "regulatory reliance" truly means for your quality and post-market surveillance strategy. **Burning Questions for This Episode:** * Which specific device categories are eligible for the new COFEPRIS-FDA fast-track program? * What exact FDA documentation is now required for a streamlined submission to COFEPRIS? * How does this reliance pathway change the responsibilities of your Mexican Registration Holder? * What are the new, immediate post-market reporting obligations under this program? * Is this accelerated pathway a sign of a permanent shift in Mexican regulatory policy? * How can you leverage your existing 510(k) or PMA to maximize this opportunity? * What are the hidden compliance risks that could disqualify you from the program? At Pure Global, we specialize in navigating these complex regulatory shifts. We offer end-to-end solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline market access in over 30 countries, including Mexico. Whether you need to prepare a dossier for this new pathway or develop a broader LATAM strategy, our team is here to help. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

Brazil's medical device market is undergoing a seismic shift. The national regulator, ANVISA, has just released RDC 848/2024, a sweeping new resolution that redefines the essential safety and performance requirements for all medical devices and IVDs. This isn't just a simple update; it's a new paradigm that demands a total lifecycle approach to compliance and introduces stringent new rules for high-tech areas like software and cybersecurity. This episode breaks down exactly what this means for manufacturers, especially those from outside Latin America. We reveal the hidden hurdles that can derail your product launch and lead to costly delays. For example, a US-based company with FDA clearance found its market entry plan blocked overnight, needing a complete overhaul of its technical dossier to meet Brazil's new, specific cybersecurity and clinical data requirements, delaying their launch by eight months. Key Takeaways: - How does ANVISA's RDC 848/2024 impact your current Brazil registration strategy? - Are your device's cybersecurity protocols robust enough for the new, explicit requirements? - What are the biggest compliance gaps this regulation creates for devices already approved in the EU or US? - Why is a 'total lifecycle' approach to risk management now mandatory for market access in Brazil? - How can you proactively update your technical dossier to prevent rejection under these new rules? - What specific clinical evidence is now required to prove performance claims to ANVISA? - Does this new regulation affect your post-market surveillance obligations? At Pure Global, we offer end-to-end regulatory consulting solutions for MedTech and IVD companies to streamline global market access. We combine local expertise in over 30 markets, including Brazil, with advanced AI to navigate complex changes like RDC 848/2024, ensuring your path to market is efficient and successful. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

This week, we dive into a major regulatory shift in Brazil. ANVISA has just launched an exciting fast-track approval process for AI-powered medical software, creating a huge opportunity for MedTech innovators to enter Latin America's biggest market faster than ever before. But this new speed comes with a hidden challenge. The new pathway is tied to incredibly strict data privacy and cybersecurity rules based on Brazil's LGPD. These new requirements around data storage and patient consent are already creating significant hurdles, turning a golden opportunity into a complex compliance trap for unprepared companies. We explore a real-world case of a US MedTech company whose Brazilian launch was stopped in its tracks by these new data privacy rules, forcing them into a difficult and expensive decision. Their cutting-edge diagnostic tool is ready, but their data is not. Key Takeaways This Episode: 1. What are the specific criteria for ANVISA's new AI software fast-track pathway? 2. How do Brazil's new data privacy mandates specifically impact MedTech device submissions? 3. Will your existing international clinical data be considered valid under the new patient consent rules? 4. What are the real costs and penalties for non-compliance with Brazil's data localization requirements? 5. Does the new regulation give local Brazilian MedTech companies an unfair advantage? 6. How can you redesign your regulatory strategy to seize the fast-track opportunity while avoiding the privacy trap? 7. What specific cybersecurity vulnerabilities is ANVISA now targeting in its assessments? Struggling to keep up with the dynamic regulatory landscape in Latin America? At Pure Global, we offer end-to-end regulatory consulting for MedTech and IVD companies. We combine local, on-the-ground expertise in markets like Brazil with advanced AI tools to streamline your global market access. Don’t let complex regulations be a barrier to entry. Contact us at info@pureglobal.com or visit us at https://pureglobal.com/ to learn how we can accelerate your path to market.

In this episode, we dissect a sudden, unannounced regulatory shift from Brazil's ANVISA that is impacting the global Software as a Medical Device (SaMD) industry. Last week, the agency mandated a new, complex cybersecurity audit for all SaMD products, to be conducted exclusively by a short list of local Brazilian firms. This surprise move creates a significant new hurdle for market access. We explore the immediate consequences of this decision, discussing the operational and financial strains it places on international MedTech companies aiming to enter or expand within Latin America's largest market. Imagine your product launch, years in the making, being halted indefinitely by a bureaucratic requirement you had no way to anticipate. This is the critical pain point for SaMD manufacturers today, forcing them to scramble for local expertise and navigate a vague, complex, and costly new compliance layer. What you'll learn in this episode: - What are the specific, technical demands of ANVISA's new cybersecurity audit? - Why was this critical requirement left off the official public regulatory agenda? - How can you vet and manage the newly-approved local audit firms from abroad? - What does this move signal about Brazil's strategy for digital health sovereignty? - Are other LATAM countries like Mexico or Colombia likely to follow Brazil's lead? - How can you update your regulatory strategy to protect against these types of surprise hurdles? - What are the immediate steps to take if your SaMD submission is currently in progress? At Pure Global, we specialize in turning these regulatory challenges into market opportunities. With our local experts and advanced AI-driven data tools, we provide end-to-end regulatory consulting to streamline your market access. For help navigating the complexities of the Brazilian market, contact us at info@pureglobal.com or visit https://pureglobal.com/.

This week, we dissect the groundbreaking new regulation from Brazil's ANVISA. A new fast-track approval pathway for AI and Machine Learning medical software promises to slash market entry timelines, opening the door for innovative diagnostic technologies to reach one of LATAM's biggest markets. However, a critical and complex clause lurks within the fine print: a strict data residency requirement. We explore how this 'data trap' creates significant operational and financial hurdles for foreign MedTech companies, potentially offsetting the benefits of the accelerated review process and reshaping market entry strategies for the entire region. Imagine you're a startup with a revolutionary AI diagnostic tool. You see ANVISA's announcement and plan your Brazilian launch, only to discover you must now build or lease an entire local data infrastructure, navigating both healthcare and data privacy laws. We look at the real-world costs and strategic pivots this requires. Key questions from this episode: - What specific types of AI medical software are eligible for ANVISA's new fast-track? - How does the data residency requirement change the cost-benefit analysis for entering Brazil? - What are the key differences between Brazil's LGPD and GDPR that companies must consider? - Are there compliant local cloud providers in Brazil ready for this MedTech influx? - Could this regulation set a new data sovereignty precedent for other LATAM markets? - What are the immediate steps a company should take if they were targeting Brazil with their AI software? - How does this impact the valuation and investment appeal of foreign AI MedTech startups? Pure Global offers end-to-end regulatory consulting solutions for Medical Technology and In-Vitro Diagnostic companies, combining local expertise with advanced AI and data tools to streamline global market access. Contact Pure Global at info@pureglobal.com or visit us at https://pureglobal.com/.

This week on LATAM MedTech Insights, we dissect the breaking news from Brazil. ANVISA has unexpectedly tightened its cybersecurity regulations for Software as a Medical Device (SaMD), creating significant new challenges for manufacturers aiming to enter or remain in Latin America's largest market. We uncover the specific documentation now required and explain why your existing FDA or CE marking might not be enough. This episode delves into the real-world impact of these changes. Imagine your state-of-the-art health app, already successful in the U.S. and Europe, is suddenly halted at the Brazilian border. Your dossier is rejected for failing to meet new, highly specific cybersecurity criteria. This is the new reality for many, causing costly delays and demanding a complete overhaul of regulatory strategy. Key questions answered in this episode: - What are the three critical documents ANVISA now demands for SaMD cybersecurity? - How can you leverage your existing international documentation for the new Brazilian requirements? - Is on-the-ground cybersecurity testing now mandatory in Brazil? - What are the most common pitfalls leading to dossier rejection under the new framework? - How can proactive post-market surveillance protect you from a product recall? - Does the new rule apply to legacy devices already on the market? - How will this impact the timeline and cost of entering the Brazilian market? Struggling with global market access? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, using local expertise and advanced AI to streamline market entry. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

This episode of LATAM MedTech Insights dives deep into the lingering challenges of Brazil's landmark medical device regulation, ANVISA RDC 751. Years after its implementation, we explore the real-world operational hurdles that international MedTech companies continue to face, moving beyond the basics to uncover the hidden complexities in risk classification, technical documentation, and post-market surveillance. We analyze the costly surprises that arise from device reclassification. For instance, a manufacturer of orthopedic implants saw their product up-classified from Class II to Class III, triggering unexpected requirements for extensive, local clinical data. This single issue delayed their market entry by over a year and added hundreds of thousands of dollars in unplanned expenses, a critical pain point for any company looking to expand into Latin America's largest market. Key Questions Answered in this Episode: - Is your device's risk class under RDC 751 secretly jeopardizing your launch timeline? - How can you manage the intensive new Technical Dossier requirements without draining resources? - What are the most common post-market surveillance mistakes companies are making in Brazil? - Why is your choice of a Brazil Registration Holder (BRH) more critical than ever? - Are you prepared for ANVISA's increased scrutiny on clinical data for medium-risk devices? - How does Brazil's harmonization with global standards create both opportunities and traps? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies. We combine local expertise with advanced AI and data tools to streamline your global market access, ensuring you navigate complex markets like Brazil with confidence. For a strategic partner in your global expansion, contact us at info@pureglobal.com or visit https://pureglobal.com/.

Brazil's MedTech market is undergoing a seismic regulatory shift. ANVISA, the national health surveillance agency, is rolling out a series of major updates, including the new RDC 848/2024, which redefines essential safety and performance requirements with a strong focus on lifecycle risk management and cybersecurity. This is creating a new, complex web of compliance for manufacturers. This episode of LATAM MedTech Insights unpacks the practical implications of these changes. We go beyond the headlines to explore the operational hurdles, such as the mandatory transition to a new digital certificate platform by 2025. We reveal the hidden pitfalls that are already causing submission delays and rejections for unprepared foreign companies trying to enter or stay in Latin America's largest market. We explore the real-world scenario of a mid-sized European device maker whose Brazilian market entry was stalled for six months. They successfully passed clinical trials, but their entire submission was rejected due to a documentation technicality in ANVISA’s new, confusing certificate issuance system. This episode breaks down how to avoid that costly mistake. Key Takeaways: 1. How does ANVISA's new RDC 848/2024 fundamentally change safety requirements for your device? 2. Is your current technical dossier prepared for the upcoming cybersecurity mandates? 3. What are the biggest pitfalls when transitioning from the old 'Sicert' to the new submission platform? 4. Why might your existing risk classification under RDC 751 need urgent re-evaluation? 5. How will these new rules impact your timeline and budget for entering the Brazilian market? 6. Are you treating Brazilian compliance as a lifecycle activity or a one-time submission? 7. What specific documentation changes are required for the new 2025 certificate tool? Don't let regulatory hurdles block your access to the vibrant Brazilian market. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, combining deep local expertise with advanced AI tools to streamline global market access. We act as your local representative, manage technical dossiers, and ensure continuous compliance in over 30 markets. To build a resilient regulatory strategy for Brazil and beyond, contact us at info@pureglobal.com or visit https://pureglobal.com/.

This week, we dive into a sudden and critical regulatory update from Brazil's ANVISA that is sending ripples through the AI medical device community. A new technical clarification has redefined the rules for software-based devices, creating unexpected and costly new hurdles for foreign manufacturers trying to enter Latin America's biggest market. We explore the two main challenges this clarification presents: a new, strict requirement for clinical data from the Brazilian population, and complex cybersecurity documentation mandates that must be localized in Portuguese and aligned with local data laws. This episode breaks down what these changes mean on the ground and why your existing global regulatory dossier may no longer be enough for Brazil. A German MedTech scaleup, with a cutting-edge AI diagnostic software already CE-marked, targeted Brazil for its next major expansion. They prepared their submission based on the existing RDC 751 regulation, using their robust European clinical trial data. Their submission was just put on hold by ANVISA last week. The reason? The new technical note requires clinical validation on the Brazilian population, data they do not have. Now, they face an unexpected delay of at least 12-18 months to conduct a local study, a costly setback that puts their entire LATAM strategy at risk. Key questions from this episode: - Is your existing clinical data package now obsolete for your ANVISA submission? - What are the specific requirements for validating an AI algorithm on the Brazilian population? - Does your cybersecurity risk assessment comply with Brazil's LGPD data law? - Are you prepared to submit highly technical documents in flawless, localized Portuguese? - How can you conduct a supplementary local clinical study without a physical presence in Brazil? - What are the hidden costs associated with this new ANVISA clarification? - Could a local regulatory partner help you bypass the need for a full new clinical trial? Don't let regulatory surprises derail your entry into Latin America's largest market. Pure Global combines deep local expertise with advanced AI tools to navigate complex requirements like Brazil's new SaMD regulations. We provide end-to-end support, from regulatory strategy and local representation to compiling the technical dossier needed to succeed. Let us be your partner in streamlining global market access. Contact us at info@pureglobal.com or visit us at https://pureglobal.com/.